Should you buy these healthcare shares?

Should you buy CSL Limited (ASX:CSL) shares and two others in the healthcare sector?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

a woman

One of the best performing areas of the share market over the last 12 months has been the healthcare sector.

During this time the S&P/ASX 200 Health Care (Index: ^AXHJ) (ASX: XHJ) has managed to put on a gain of almost 27%.

While I wouldn't necessarily expect the sector to replicate this gain over the next 12 months, thanks to Australia's ageing population and increasing chronic disease burden I still believe it could continue to outperform the rest of the market.

With that in mind, should you buy these three healthcare shares?

CSL Limited (ASX: CSL)

The strong performance of this biotherapeutics company's shares over the last 12 months have played a key role in taking the S&P/ASX 200 Health Care index higher. While this leaves its shares close to an all-time high, I don't think it is too late to invest if you're prepared to hold them for the long-term. However, if you're more focused on the short term you might want to wait in hope of a pullback in its share price before investing.

Nanosonics Ltd (ASX: NAN)

I'm a big fan of this infection control specialist and believe it could have a very bright future ahead of it. Especially given its plan to release complementary products in the near future that will both boost and diversify its revenue. One thing of note, though, is that the company is currently being targeted by short sellers and is one of the most shorted shares on the Australian share market. It is unclear why short sellers have taken an interest, which does leave me concerned that they know something that I don't. Because of this, I'm staying clear of Nanosonics until short interest fades.

Ramsay Health Care Limited (ASX: RHC)

Ramsay Health Care is one of the world's leading private hospital operators. Whilst I am a huge fan of Ramsay and would love to have it in my portfolio, I'm keeping away from the company until its shares are trading at a level more befitting of its current growth profile. At present Ramsay's growth is being held back by weakness in Europe and falling private hospital coverage here in Australia.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why are Telix shares sinking 7.5% today?

Let's see what this healthcare stock has announced today.

Read more »

A smiling businessman sits at a desk with bags of mony, indicating a share price rise after funding has been approved
Healthcare Shares

Telix Pharmaceuticals upsizes convertible bonds to US$600 million

Telix Pharmaceuticals has upsized its convertible bond issue to US$600 million, enhancing financial flexibility and repurchasing existing bonds.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Healthcare Shares

Telix Pharmaceuticals Investor Presentation: 56% FY25 revenue growth, pipeline advances

Telix Pharmaceuticals books 56% higher FY25 revenue, advances clinical pipeline, and issues upbeat FY26 guidance.

Read more »

A woman looks unimpressed on a blue background.
Healthcare Shares

What on earth's going on with CSL shares?

CSL’s growth slowed, and its premium valuation reset hard.

Read more »

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

Why Clarity Pharmaceuticals shares just fell 5% on today's announcement

Investors are balancing Clarity's long-term potential against near-term uncertainty.

Read more »